St. Jude Medical RESPECT Trial for PFO Closure Provides Clinical Evidence of Risk Reduction in Prevention of Recurrent Cryptogenic Stroke
St. Jude Medical, Inc. (NYSE: STJ), a medical device company, today
announced results from its RESPECT trial, which studied the AMPLATZER™
PFO Occluder in the prevention of recurrent cryptogenic stroke. Evidence
presented at a late breaking trial session during the 24th
Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific
symposium, sponsored by the Cardiovascular Research Foundation, shows
that the primary analysis was not statistically significant but trended
towards superiority, while additional analyses demonstrated superiority.
Stroke risk reduction was observed across the totality of analyses with
rates ranging from 46.6 percent - 72.7 percent.
According to the World Health Organization (WHO), an estimated 15
million strokes occur worldwide each year. In 2010, stroke cost the